SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Kerala Ayurveda informs about press release

19 Jul 2025 Evaluate

Kerala Ayurveda has informed that KAL reports 44% revenue growth in Q1 26 vs. PY (38% growth excluding Ayurvedagram Bali). Adjusted EBITDA* positive at Rs.6.4 Crs (+Rs.5.4 Crs. vs. PY) with continued investment in talent hiring, marketing and building infrastructure over the first quarter of 2026. KAL continues on its path to Double the growth rate in 2026 to 50% topline growth with investments in chosen drivers of growth - the Digital and Health service businesses powered by world class talent, marketing, technology and international expansion. Press release regarding the same enclosed.

The above information is a part of company’s filings submitted to BSE.

Kerala Ayurveda Share Price

246.65 4.40 (1.82%)
17-Apr-2026 15:41 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1239.00
Cipla 1238.30
Zydus Lifesciences 938.00
Lupin 2321.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×